Thus, pharmacologic inhibition of CD73/adenosine signaling is an attractive approach to increase the therapeutic ratio in the RT of thoracic tumors with high risk of adverse late effects in the highly radiosensitive normal lung tissue by (i) dampening growth and metastasis of lung tumors, (ii) enhancing the radiation-induced activation of the antitumor immune response, (iii) by restricting the immunosuppressive action of CD39/CD73 on circulating immune cells, and (iv) attenuating adverse late effects in the lung. This evidence concerns the gene NT5E and neoplasm of thorax.